Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Abstract Text:

ABSTRACT: BACKGROUND: To use amifostine concurrently with radiochemotherapy (CT-RT) or radiotherapy (RT) alone in order to prevent dry eye syndrome in patients with malignancies located in the fronto-orbital region. METHODS: Five patients (2 males, 3 females) with diagnosed malignancies (Non-Hodgkin B-cell Lymphoma, neuroendocrine carcinoma) involving the lacrimal gland, in which either combined CT-RT or local RT were indicated, were prophylactically treated with amifostine (500 mg sc). Single RT fraction dose, total dose and treatment duration were individually adjusted to the patient's need. Acute and late adverse effects were recorded using the RTOG score. Subjective and objective dry eye assessment was performed for the post-treatment control of lacrimal gland function. RESULTS: All patients have completed CT-RT or RT as indicated. The median total duration of RT was 29 days (range, 23 - 39 days) and the median total RT dose was 40 Gy (range, 36 - 60 Gy). Median lacrimal gland exposure was 35.9 Gy (range, 16.8 - 42.6 Gy). Very good partial or complete tumor remission was achieved in all patients. The treatment was well tolerated without major toxic reactions. Post-treatment control did not reveal in any patient either subjective or objective signs of a dry eye syndrome. CONCLUSION: The addition of amifostine to RT/CT-RT of patients with tumors localized in orbital region was found to be associated with absence of dry eye syndrome.

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Radiation oncology (London, England)

VOLUME: 3

Page Numbers: 22

Journal Abbreviation:

ISSN: 1748-717X

DAY: 1

MONTH: 09

YEAR: 2008

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101265111

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.

AFFILIATION: Department of Ophthalmology, University Basel, University Hospital Basel, Switzerland. dgoldblum@uhbs.ch.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Radiat Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study Related Publications

• A high-quality catalog of the Drosophila melanogaster proteome.
• A statistical method for chromatographic alignment of LC-MS data.
• Advances in proteomic workflows for systems biology.
• Analysis of protein complexes using mass spectrometry.
• Analysis of the Saccharomyces cerevisiae proteome with PeptideAtlas.
• Building consensus spectral libraries for peptide identification in proteomics.
• Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide.
• Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics.
• Development and validation of a spectral library searching method for peptide identification from MS/MS.
• High-accuracy proteome maps of human body fluids.
• Identification of cross-linked peptides from large sequence databases.
• Isotopes for medicine.
• Mass spectrometric detection of tissue proteins in plasma.
• Optimized peptide separation and identification for mass spectrometry based proteomics via free-flow electrophoresis.
• PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows.
• PhosphoPep--a phosphoproteome resource for systems biology research in Drosophila Kc167 cells.
• Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.
• Progress against cancer with radioisotopes.
• Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation.
• Quantitative proteomic analysis of the budding yeast cell cycle using acid-cleavable isotope-coded affinity tag reagents.
• Quantitative proteomic analysis to profile dynamic changes in the spatial distribution of cellular proteins.
• Reproducible isolation of distinct, overlapping segments of the phosphoproteome.
• Selected reaction monitoring for quantitative proteomics: a tutorial.
• Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring.
• The role of the Atomic Energy Commission in the future work with isotopes.
• UniPep--a database for human N-linked glycosites: a resource for biomarker discovery.
• Using stable isotope tagging and mass spectrometry to characterize protein complexes and to detect changes in their composition.
• [AIDS--care--sexuality]
• [Angiogenesis as prognostic factor in malignant tumors]
• [Radiotherapy of the prostate gland--old wine in a new bottle?]